A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76867 | Ravulizumab | 1803171-55-2 | 98% |
Ravulizumab
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity... | ||||
T76866 | Icrucumab | 1024603-92-6 | 98% |
|
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ... | ||||
T76864 | Enapotamab | 1912423-61-0 | 98% |
Enapotamab
|
Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin). | ||||
T76863 | Elezanumab | 1791416-49-3 | 98% |
|
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 ... | ||||
T76861 | Cinpanemab | 2094516-02-4 | 98% |
Cinpanemab
|
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease an... | ||||
T76858 | Ascrinvacumab | 1463459-96-2 | 98% |
Ascrinvacumab
|
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ... | ||||
T76857 | Anetumab | 1954758-84-9 | 98% |
|
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-act... | ||||
T76856 | Andecaliximab | 1518996-49-0 | 98% |
Andecaliximab
|
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model o... | ||||
T76844 | Abciximab | 143653-53-6 | 98% |
Abciximab
|
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leuk... | ||||
T76831 | Tesidolumab | 1531594-08-7 | 98% |
Tesidolumab
|
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cuttin... | ||||
T76828 | Sonepcizumab | 1031360-18-5 | 98% |
Sonepcizumab
|
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. Sonepcizumab has anti-cancer activity and can be used to study metastatic renal cell... | ||||
T76815 | Lexatumumab | 845816-02-6 | 98% |
Lexatumumab
|
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant meso... | ||||
T76810 | Ganitumab | 905703-97-1 | 98% |
Ganitumab
|
Ganitumab (AMG 479) is a highly potent monoclonal antibody to type 1 insulin-like growth factor receptor (IGF1R). Ganitumab is recognized to bind to IGF1R at low... | ||||
T76796 | Patritumab | 1262787-83-6 | 98% |
|
Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritu... | ||||
T76794 | Ulocuplumab | 1375830-34-4 | 98% |
Ulocuplumab
|
Ulocuplumab (BMS-936564) is a fully human anti-CXCR4 IgG4 antibody.Ulocplumab exhibits antitumor activity in acute myeloid leukemia (AML), non-Hodgkin's lymphoma... | ||||
T76790 | Inotuzumab | 1660159-36-3 | 98% |
Inotuzumab
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. Inotuzumab is a naked antibody to Inotuzumab ozogamicin and ca... | ||||
T76788 | Demcizumab | 1243262-17-0 | 98% |
Demcizumab
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent Notch pathway inhibitor. Demcizumab is effective in multiple cancer models, bo... | ||||
T76784 | Tildrakizumab | 1326244-10-3 | 98% |
Tildrakizumab
|
Tildrakizumab (SCH 900222) is a potent humanized monoclonal antibody against IL-23 (p19 subunit). Tildrakizumab targets single-stranded IL-23 with a Kd value of ... | ||||
T76782 | Mogamulizumab | 1159266-37-1 | 98% |
Mogamulizumab
|
Mogamulizumab (KW-0761) is a monoclonal antibody against T cell CC chemokine receptor 4. Mogamulizumab has anticancer activity, eliminating tumor cells through a... | ||||
T76781 | Itolizumab | 1116433-11-4 | 98% |
Itolizumab
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that humanizes the extracellular SRCR distal domain 1 of CD6. Itol... |